Sector News

Pfizer to shutter two UK sites

November 10, 2016
Life sciences

Drugs giant Pfizer has announced plans to close two of its three key UK supply sites, but insists the decision has nothing to do with Brexit.

According to media reports, the firm’s manufacturing site in Park Royal, London, as well as its global cold chain packaging and distribution facility in Portsmouth will be closed in 2017 and 2020 respectively, with around 370 job losses in total.

“This review process has been going on since 2010 and the team just felt there were more production capabilities at the site in Belgium to support future demand and to ensure we can support the supply chain,” explained a spokesman for the firm, as reported by The Telegraph.

“The UK has a tricky commercial environment and doesn’t always link life sciences investment to the way patients use medicines, but this decision is not linked to Brexit or medicines access”.

Pfizer sold its flagship UK facilities in Sandwich, Kent, back in 2012, but around 700 of its employees remain employed at the Discovery Park science and business hub which is now housed there, and it still currently employs around 2,700 people at sites across the country.

By Selina McKee

Source: Pharma Times

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach